Page 4 - பேர்ல்முத்தேர் புற்றுநோய் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Targeted therapy shrank tumors, shows promise in improving survival June 4, 2021 SHARE Medical oncologist and senior author of a new lung cancer study, Ramaswamy Govindan, MD, of Washington University School of Medicine in St. Louis, talks about the newly FDA-approved drug sotorasib. The new study shows that sotorasib benefits some patients who have non-small-cell lung cancer that has a specific mutation in the KRAS gene. Ongoing clinical trials for lung cancer patients are investigating combinations of sotorasib plus other experimental drugs. (Video: Huy Mach/School of Medicine) The new drug sotorasib reduces tumor size and shows promise in improving survival among patients with lung tumors caused by a specific DNA mutation, according to results of a global phase 2 clinical trial. The drug is designed to shut down the effects of the mutation, which is found in about 13% of patients with lung adenocarcinoma, a common type of non-small-cell lung cancer.

New yorkUnited statesMemorial sloan kettering cancer centerRamaswamy govindanVamsidhar velchetiLangone healthOncology at washington universityAmerican society of clinical oncologyNational institutes of healthDrug administrationMd anderson cancer centerWashington university school of medicineSiteman cancer centerWashington universityAnheuser buschPerlmutter cancer center